Working… Menu

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis (FILOSOPHY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04871919
Recruitment Status : Recruiting
First Posted : May 4, 2021
Last Update Posted : July 14, 2021
Information provided by (Responsible Party):
Galapagos NV

Brief Summary:
An observational study to describe the effectiveness, safety, and patient-reported outcomes in patients with moderate to severe active rheumatoid arthritis (RA) receiving filgotinib in real-world setting.

Condition or disease Intervention/treatment
Rheumatoid Arthritis Drug: Filgotinib

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective, Non-interventional Study of the Effectiveness, Safety, and Health Related Outcomes in Patients With Moderate to Severe Active Rheumatoid Arthritis Receiving Filgotinib
Actual Study Start Date : May 11, 2021
Estimated Primary Completion Date : July 2025
Estimated Study Completion Date : July 2025

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Individuals will receive treatment for moderate to severe active rheumatoid arthritis with at least one dose of filgotinib in accordance with the product label
Drug: Filgotinib
Tablets are administered in accordance with the product label
Other Name: Jyseleca

Primary Outcome Measures :
  1. Treatment persistence rates [ Time Frame: Up to 24 months ]
    To evaluate the treatment persistence rate at 24 months, defined as the rate of patients continuing to receive filgotinib 24 months from treatment initiation.

Secondary Outcome Measures :
  1. patients' assessment of pain, Visual Analogue Scale (Pain VAS) [ Time Frame: Up to 24 months ]
  2. patients' assessment of fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F score) [ Time Frame: Up to 24 months ]
  3. patients' assessment of Work Productivity and Activity Impairment: Rheumatoid Arthritis (WPAI-RA) [ Time Frame: Up to 24 months ]
  4. medication adherence, compliance questionnaire rheumatology 19 (CQR19) [ Time Frame: Up to 24 months ]
  5. Number of adverse events and serious adverse events [ Time Frame: Up to 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study population will consist of patients aged ≥ 18 years with moderate to severe active RA receiving filgotinib who will be enrolled across participating countries within Europe.

Inclusion Criteria:

  • Patients aged ≥ 18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local standard of care and product label for the first time.
  • Patients must be willing and able to use an electronic device to complete the study patient-reported outcome (PRO).

Exclusion Criteria:

- Participation in any other interventional or non-interventional study without prior approval from the Medical Monitor. This does not preclude inclusion of patients enrolled to national registries.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04871919

Layout table for location contacts
Contact: Galapagos Medical Information +3215342900

Layout table for location information
Rheumazentrum Kupka Recruiting
Altenburg, Germany, 4600
Praxis für Rheumatologie - Amberg Recruiting
Amberg, Germany, 92224
Rheumatology Center Prof. Neeck Recruiting
Bad Doberan, Germany, 18209
Fachklinik Bad Pyrmont Rheumazentrum Recruiting
Bad Pyrmont, Germany, 31812
Rheumatologische Schwerpunktpraxis Recruiting
Berlin, Germany, 12161
Rheumatologische Praxis Recruiting
Braunschweig, Germany, 38100
Praxis Dilltal Recruiting
Ehringshausen, Germany, 35630
MVZ Ambulantes Rheumazentrum Erfurt Recruiting
Erfurt, Germany, 99096
Rheumazentrum Ruhrgebiet Recruiting
Herne, Germany, 44649
Praxis für Internistische Rheumatologie Recruiting
Leipzig, Germany, 04129
Fachpraxis für Rheumatologie und Osteologie Recruiting
Nienburg, Germany, 31582
Medizinischen Versorgungszentrums für Rheumatologie Recruiting
Planegg, Germany, 82152
Rheumahaus - GbR Recruiting
Potsdam, Germany, 14469
Sponsors and Collaborators
Galapagos NV
Layout table for investigator information
Study Director: Galapagos Study Director Galapagos NV
Layout table for additonal information
Responsible Party: Galapagos NV Identifier: NCT04871919    
Other Study ID Numbers: GLPG0634-CL-401
EUPAS39767 ( Registry Identifier: EU PAS Register )
First Posted: May 4, 2021    Key Record Dates
Last Update Posted: July 14, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Galapagos NV:
patient reported outcome
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases